Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently ...
In pathology-ridden layers of the cortex, synaptic genes faded while inflammation flared. In women, inflammatory and vascular pathways stood out, while neuron and oligodendrocyte disease signatures ...
There are three ongoing ICI Trials testing optimal perturbation of the tumor immune system and rate of pathologic response, this are the NESCIO trial, the SPARC-1 and NAPSTER. The NESCIO trial ...